PDF(Pubmed)
Abstract：
BACKGROUND: We aimed to assess medication risks and determine factors influencing the health-related quality of life (HRQOL) in cancer inpatients.
METHODS: A retrospective analysis was conducted to identify drug-related problems (DRPs) based on medication reviews, including patient-reported outcomes (PROs). Multiple linear regression analyses were performed to identify sociodemographic, disease-related, and drug therapy-related factors influencing changes from hospital admission to discharge in the scales of the EORTC QLQ-C30 questionnaire.
RESULTS: A total of 162 inpatients with various hematological and solid cancer diseases was analyzed. Patients received a mean of 11.6 drugs and 92.6% of patients exhibited polymedication resulting in a mean of 4.0 DRPs per patient. Based on PRO data, 21.5% of DRPs were identified. Multiple linear regression models described the variance of the changes in global HRQOL and physical function in a weak-to-moderate way. While drug therapy-related factors had no influence, relapse status and duration of hospital stay were identified as significant covariates for global HRQOL and physical function, respectively.
CONCLUSIONS: This analysis describes underlying DRPs in a German cancer inpatient population. PROs provided valuable information for performing medication reviews. The multiple linear regression models for global HRQOL and physical function provided explanations for changes during hospital stay.
METHODS: A retrospective analysis was conducted to identify drug-related problems (DRPs) based on medication reviews, including patient-reported outcomes (PROs). Multiple linear regression analyses were performed to identify sociodemographic, disease-related, and drug therapy-related factors influencing changes from hospital admission to discharge in the scales of the EORTC QLQ-C30 questionnaire.
RESULTS: A total of 162 inpatients with various hematological and solid cancer diseases was analyzed. Patients received a mean of 11.6 drugs and 92.6% of patients exhibited polymedication resulting in a mean of 4.0 DRPs per patient. Based on PRO data, 21.5% of DRPs were identified. Multiple linear regression models described the variance of the changes in global HRQOL and physical function in a weak-to-moderate way. While drug therapy-related factors had no influence, relapse status and duration of hospital stay were identified as significant covariates for global HRQOL and physical function, respectively.
CONCLUSIONS: This analysis describes underlying DRPs in a German cancer inpatient population. PROs provided valuable information for performing medication reviews. The multiple linear regression models for global HRQOL and physical function provided explanations for changes during hospital stay.
摘要：
背景：我们旨在评估癌症住院患者的用药风险并确定影响健康相关生活质量（HRQOL）的因素。
方法：进行回顾性分析，以根据药物回顾确定药物相关问题（DRPs）。包括患者报告的结果（PRO）。进行多元线性回归分析以确定社会人口统计学，疾病相关,在EORTCQLQ-C30问卷量表中，影响从入院到出院变化的药物治疗相关因素。
结果：共分析了162名患有各种血液系统和实体癌疾病的住院患者。患者平均接受11.6种药物，92.6％的患者表现出多种药物治疗，导致每位患者平均4.0DRP。根据PRO数据，21.5%的DRPs被鉴定。多元线性回归模型以弱到中等的方式描述了全球HRQOL和身体功能变化的方差。虽然药物治疗相关因素没有影响，复发状态和住院时间被确定为全球HRQOL和身体功能的重要协变量，分别。
结论：该分析描述了德国癌症住院患者人群中潜在的DRP。PRO为进行药物审查提供了有价值的信息。全局HRQOL和身体功能的多元线性回归模型为住院期间的变化提供了解释。
方法：进行回顾性分析，以根据药物回顾确定药物相关问题（DRPs）。包括患者报告的结果（PRO）。进行多元线性回归分析以确定社会人口统计学，疾病相关,在EORTCQLQ-C30问卷量表中，影响从入院到出院变化的药物治疗相关因素。
结果：共分析了162名患有各种血液系统和实体癌疾病的住院患者。患者平均接受11.6种药物，92.6％的患者表现出多种药物治疗，导致每位患者平均4.0DRP。根据PRO数据，21.5%的DRPs被鉴定。多元线性回归模型以弱到中等的方式描述了全球HRQOL和身体功能变化的方差。虽然药物治疗相关因素没有影响，复发状态和住院时间被确定为全球HRQOL和身体功能的重要协变量，分别。
结论：该分析描述了德国癌症住院患者人群中潜在的DRP。PRO为进行药物审查提供了有价值的信息。全局HRQOL和身体功能的多元线性回归模型为住院期间的变化提供了解释。
